Latest News and Press Releases
Want to stay updated on the latest news?
-
Orlando, FL, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp. (OTC Pink: IMUN) (“Biostax”), a hub-and-spoke biotech development engine, announces the signing of a...
-
ORLANDO, March 01, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC Pink: IMUN) ("Immune" or "IMUN"), a specialty pharmaceutical company involved in the acquisition, development and...
-
Orlando, FL, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC PINK:IMUN) (“Immune” or “IMUN”) today announced that its Chief Executive Officer, President, and Director, Stephen...
-
ORLANDO, FL, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC PINK:IMUN) ("Immune" or "IMUN"), a specialty pharmaceutical company involved in the acquisition, development, and...
-
ORLANDO, FL, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC PINK:IMUN) ("Immune" or "IMUN"), a pioneering pharmaceutical company involved in the acquisition, development, and...
-
ORLANDO, FL, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC PINK:IMUN) (“Immune” or “IMUN”), a specialty pharmaceutical company involved in the acquisition, development, and...
-
ORLANDO, FL, July 22, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC Pink: IMUN) (“Immune” or “IMUN”), a specialty pharmaceutical company involved in the acquisition, development and...
-
ORLANDO, Fla, June 03, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC:BB IMUN), a specialty pharmaceutical company involved in the development, commercialization, distribution and marketing...